Investment Analysts’ Recent Ratings Updates for Aclaris Therapeutics (ACRS)

Several analysts have recently updated their ratings and price targets for Aclaris Therapeutics (NASDAQ: ACRS):

  • 1/29/2019 – Aclaris Therapeutics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 1/23/2019 – Aclaris Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “
  • 1/19/2019 – Aclaris Therapeutics was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 1/12/2019 – Aclaris Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 1/8/2019 – Aclaris Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “
  • 1/2/2019 – Aclaris Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 1/2/2019 – Aclaris Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 12/28/2018 – Aclaris Therapeutics was given a new $50.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 12/24/2018 – Aclaris Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “
  • 12/22/2018 – Aclaris Therapeutics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 12/21/2018 – Aclaris Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $7.75 price target on the stock. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “
  • 12/21/2018 – Aclaris Therapeutics was given a new $50.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 12/15/2018 – Aclaris Therapeutics was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 12/6/2018 – Aclaris Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “
  • 12/4/2018 – Aclaris Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $11.00 price target on the stock. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “
  • 12/1/2018 – Aclaris Therapeutics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.

Shares of ACRS traded up $0.17 on Wednesday, hitting $6.89. The company’s stock had a trading volume of 3,066 shares, compared to its average volume of 438,069. The company has a market capitalization of $280.85 million, a P/E ratio of -2.76 and a beta of 1.59. Aclaris Therapeutics Inc has a fifty-two week low of $5.95 and a fifty-two week high of $23.32.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Tuesday, November 6th. The biotechnology company reported ($1.06) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.19. The business had revenue of $1.63 million for the quarter, compared to the consensus estimate of $1.58 million. Aclaris Therapeutics had a negative return on equity of 63.74% and a negative net margin of 1,578.24%. Sell-side analysts anticipate that Aclaris Therapeutics Inc will post -4.01 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the business. Man Group plc lifted its holdings in Aclaris Therapeutics by 396.1% during the 3rd quarter. Man Group plc now owns 402,624 shares of the biotechnology company’s stock worth $5,846,000 after buying an additional 321,458 shares in the last quarter. BlackRock Inc. lifted its holdings in Aclaris Therapeutics by 9.7% during the 2nd quarter. BlackRock Inc. now owns 2,311,641 shares of the biotechnology company’s stock worth $46,163,000 after buying an additional 204,215 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Aclaris Therapeutics by 2.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 188,380 shares of the biotechnology company’s stock worth $2,735,000 after buying an additional 4,351 shares in the last quarter. MetLife Investment Advisors LLC lifted its holdings in Aclaris Therapeutics by 32.7% during the 2nd quarter. MetLife Investment Advisors LLC now owns 13,157 shares of the biotechnology company’s stock worth $263,000 after buying an additional 3,244 shares in the last quarter. Finally, Jefferies Group LLC acquired a new position in Aclaris Therapeutics during the 3rd quarter worth $243,000. 72.37% of the stock is currently owned by hedge funds and other institutional investors.

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Read More: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply